Biodiversity and Biopiracy: IP Rights Over Natural Discoveries

Understanding Biodiversity and the Rise of Biopiracy

Can naturally occurring biological resources be patented? Who owns the knowledge that Indigenous communities have preserved for centuries? And where should the law draw the line between discovering nature and inventing from it? These questions have become increasingly significant as scientific and technological advancements continue to unlock the immense commercial potential of biodiversity.

Biodiversity, encompassing the wide variety of plants, animals, microorganisms, and ecosystems, serves as the foundation for modern pharmaceuticals, agriculture, biotechnology, and numerous industrial innovations. Many commercially valuable products are developed from naturally occurring biological resources or are inspired by the traditional knowledge of Indigenous and local communities, who have safeguarded these resources for generations. According to the Convention on Biological Diversity (CBD), nearly 80% of the world's biodiversity is found in areas inhabited or managed by Indigenous peoples, underscoring their critical role in biodiversity conservation and the importance of ensuring fair recognition and equitable benefit-sharing.

The growing scientific and commercial value of biodiversity has also increased the search for valuable biological resources, creating unprecedented opportunities for innovation. However, it has simultaneously intensified concerns over biopiracy—the unauthorized use of biological resources and associated traditional knowledge without prior informed consent or equitable sharing of benefits. These concerns gained greater prominence with the globalization of intellectual property protection through agreements such as the TRIPS Agreement, and have become even more significant as biotechnology, genomics, and artificial intelligence reshape biodiversity research and natural product discovery.

Against this backdrop, the intersection of biodiversity, biopiracy, and intellectual property has emerged as one of the most complex areas of modern patent law. This article examines the legal and ethical debates surrounding the patentability of naturally derived compounds and organisms, the ownership of biological resources and traditional knowledge, the international legal framework governing these issues, and the evolving impact of artificial intelligence on biodiversity research and intellectual property.

The Legal and Ethical Debate Surrounding Biodiversity and Patentability

The commercialization of biodiversity has generated one of the most significant debates in intellectual property law: Can naturally occurring biological resources and the knowledge associated with them become private intellectual property? While patent law seeks to reward innovation, biodiversity and traditional knowledge often pre-exist scientific discovery, creating a conflict between innovation incentives and equitable ownership. This debate extends beyond legal principles and raises broader questions of ethics, justice, and global equity.

1. Discovery versus Invention

One of the central legal questions is whether naturally occurring biological materials constitute a patentable invention or merely a discovery.

Patent law generally protects inventions that are novel, useful, and involve human ingenuity. However, many valuable pharmaceutical compounds, genes, microorganisms, and plant extracts already exist in nature. Simply identifying or isolating them does not necessarily create something new. This has created a long-standing legal distinction between discovering what already exists in nature and inventing something through substantial human intervention.

The United States has played a defining role in shaping this distinction through judicial interpretation.

• In Diamond v. Chakrabarty (1980), the Supreme Court of the United States held that a genetically engineered bacterium capable of degrading crude oil was patentable because it was a product of human ingenuity rather than a naturally occurring organism. The judgment significantly expanded the scope of biotechnology patents by recognizing that living organisms modified through human intervention could qualify for patent protection.

• More than three decades later, Association for Molecular Pathology v. Myriad Genetics, Inc. (2013) established an important limitation. The Court ruled that naturally occurring human DNA sequences are products of nature and therefore cannot be patented merely because they have been isolated. However, complementary DNA (cDNA), which is synthetically created in laboratories, remains patent-eligible because it does not occur naturally.

Together, these decisions establish an important principle in U.S. patent law: nature itself cannot be patented, but human-created modifications of natural materials may qualify for patent protection.

2. Who Owns Biological Resources?

Even where patentability requirements are satisfied, another fundamental question arises: Who owns biodiversity?

Most of the world's biodiversity is concentrated in developing countries, particularly in tropical regions inhabited by Indigenous people and local communities. These communities have often conserved biological resources and accumulated ecological knowledge over centuries.

When researchers or corporations obtain biological materials from these regions and subsequently develop commercial products, disputes emerge regarding ownership and control. While innovators may argue that scientific research and technological development justify patent protection, source countries and Indigenous communities contend that the underlying biological resources are part of their natural heritage and should not be commercially exploited without authorization.

This disagreement lies at the heart of many allegations of biopiracy. The debate over the ownership of biological resources extends beyond theoretical discussions and has been reflected in several high-profile intellectual property disputes. Among these, the Basmati rice controversy illustrates the challenges of protecting biological resources and geographically associated traditional agricultural knowledge within the international patent system.

Case Study: Basmati Rice Patent Battle

One of the most significant disputes concerning the ownership of biological resources is the Basmati rice patent controversy. In 1997, the U.S.-based company RiceTec was granted U.S. Patent No. 5,663,484 relating to certain basmati rice lines and grains. The patent sparked widespread objections from India, which argued that basmati represented a traditional agricultural resource intrinsically linked to the Indian subcontinent.

Following legal and diplomatic challenges, RiceTec withdrew 15 of its 20 patent claims, and the United States Patent and Trademark Office (USPTO) directed the company to amend the title of the patent. More importantly, the dispute highlighted the limitations of patent protection over biological resources associated with specific geographical origins and demonstrated the need for stronger protection of traditional agricultural knowledge through mechanisms such as geographical indications (GIs). For innovators and patent applicants, the case reinforced the importance of carefully defining patent claims involving biological resources and considering existing traditional and geographical rights during patent prosecution.

3. Ownership of Traditional Knowledge

The debate becomes even more complex when traditional knowledge contributes directly to scientific discovery.

Indigenous and local communities have long relied on medicinal plants, agricultural practices, and ecological knowledge that have been transmitted across generations. In many cases, this traditional knowledge guides researchers toward identifying biologically active compounds or commercially valuable resources.

The ethical dilemma arises when companies patent inventions developed from this knowledge without recognizing or compensating the communities that originally generated it.

Several important questions, therefore, remain unresolved:

• Should traditional knowledge itself receive legal protection?

• Can exclusive patent rights be justified when the original knowledge has existed collectively for centuries?

• Who should receive financial or non-financial benefits resulting from commercialization?

• What constitutes equitable benefit-sharing?

These questions continue to shape international discussions on biodiversity governance and intellectual property rights, and the practical implications of these debates are evident in several landmark biopiracy disputes, where patents granted over traditional knowledge and biological resources were subsequently challenged.

The relationship between biodiversity and intellectual property is undergoing a fundamental transformation. What began as debates over the patentability of naturally occurring compounds and the protection of traditional knowledge has evolved into a far more complex landscape shaped by biotechnology, digital genetic information, and artificial intelligence. As innovation increasingly relies on biodiversity-derived resources and AI-assisted research, the challenge is no longer confined to determining what can be patented, but also how such innovation should be governed in a manner that is scientifically progressive, legally robust, and ethically responsible.